Added 8 days ago Drug news

European Commission approves Trazimera, biosimilar trastuzumab for HER2 overexpressing breast and gastric cancer.- Pfizer

Pfizer Inc. announced the European Commission (EC) has approved Trazimera a biosimilar to Herceptin (trastuzumab), for the treatment of human epidermal...

Added 1 month ago Drug news

FDA accepts BLA for subcutaneous formulation of Herceptin for approved indications.- Genentech/Halozyme Therapeutics.

Halozyme Therapeutics announced that the FDA has accepted a Biologics License Application from Genentech, a member of the Roche Group,...

Added 1 month ago Drug news

Blueprint Medicines initiates Phase III trial of avapritinib to treat patients with advanced GIST.

Blueprint Medicines has dosed the first patient in the VOYAGER Phase III clinical trial, which is evaluating the safety and...

Gastric cancer: ESMO–ESSO–ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up

The ESMO Clinical Practice Guidelines (CPG) are intended to provide the user with a set of recommendations for the best...

Added 4 years ago

Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Neuroendocrine gastroenteropancreatic tumors (GEP-NETs) constitute a heterogeneous group of tumors with their origin in neuroendocrine cells of the embryological gut. This guideline focuses on diagnosis and pathology/molecular biology...

Added 6 years ago

BSG guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs)

Over the past few years, there have been advances in the management of neuroendocrine tumours, which have included clearer characterisation, more specific and therapeutically relevant diagnosis, and improved treatments.

Added 6 years ago

Trastuzumab-induced cardiotoxicity and its risk factors in real-world setting of breast cancer patients.

The aim of this retrospective study was to determine the frequency and timing of trastuzumab cardiotoxicity and its risk factors in real-world setting.

Added 2 months ago

Ramucirumab for the treatment of patients with gastric or gastroesophageal junction cancer in community oncology practices.

Background: Limited real-world research has investigated ramucirumab for the treatment of patients with gastric or gastroesophageal junction (GEJ) cancer.

Added 3 months ago

Ramucirumab as Second-Line Therapy in Metastatic Gastric Cancer: Real-World Data from the RAMoss Study.

Objective: The RAMoss study aimed to evaluate the safety and efficacy profile of ramucirumab in the "real-life setting".

Added 3 months ago

Enhanced Recovery After Surgery Program for Gastric Cancer: a Multi-center Study (ERASG1)

This study is aimed to evaluate the safety of applying enhanced recovery after surgery for gastric cancer.

Added 9 months ago

Study of TAS-102 or Placebo Plus BSC in Patients With Metastatic Gastric Cancer

The purpose of this trial is to compare the effects of TAS-102 and best supportive care (BSC) with Placebo (an inactive drug) and best supportive care on metastatic gastric cancer.

Added 27 days ago

A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer (RAINFALL)

The main purpose of this study is to evaluate the effectiveness of ramucirumab, which is a targeted antibody, in combination with capecitabine and cisplatin compared to capecitabine and cisplatin alone in participants with stomach cancer.

Added 8 months ago